Drug Trial Radar · NCT05029921
A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
182
Actual
Start
Dec 10, 2021
Primary completion
May 18, 2025
Study completion May 18, 2025
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Sep 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the clinical and endoscopic efficacy and safety of ustekinumab in Chinese participants with moderately to severely active Crohn's disease.
Conditions
- Crohn Disease
Interventions
UstekinumabDrug
Ustekinumab will be administered as an IV injection in induction phase and as a SC injection in maintenance phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Clinical Remission at Week 8 (Co-primary Endpoint)Time frame: Week 8
- Percentage of Participants with Endoscopic Response at Week 16 (Co-primary Endpoint)Time frame: Week 16
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, China
The Military General Hospital of Beijing PLA
Beijing, China
The second Xiangya Hospital of Central South University
Changsha, China
Changzhou No 2 Peoples Hospital
Changzhou, China
West China Hospital Sichuan University
Chengdu, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, China
The First Affiliated Hospital Sun Yat sen University
Guangzhou, China
Guangzhou First Municipal People's Hospital
Guangzhou, China
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
The Second Affiliated Hospital of Zhejiang University
Hangzhou, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, China
Anhui Province Hospital
Hefei, China
Huzhou central hospital
Huzhou, China
Jinhua municipal central hospital
Jinhua, China
The First Affiliated Hospital of NanChang University
Nanchang, China
Zhongda Hospital Southeast University
Nanjing, China
Jiangsu Province Hospital
Nanjing, China
Ningbo medical center lihuili hospital
Ningbo, China
Huashan Hospital Fudan University
Shanghai, China
Shanghai 10th Peoples Hospital
Shanghai, China
Shanghai East Hospital
Shanghai, China
Shengjing Hospital Of China Medical University
Shenyang, China
Peking University Shenzhen Hospital
Shenzhen, China
The Second Hospital Affiliated To Suzhou University
Suzhou, China
Tongji Hospital, Tongji Medical College of HUST
Wuhan, China
Renmin Hospital of Wuhan University
Wuhan, China
Wuxi People s Hospital
Wuxi, China
Yangzhou First People's Hospital
Yangzhou, China
Affiliated Hospital of Zunyi Medical University
Zunyi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.